ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ...
WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...
Clinical Trials Arena on MSN14d
NiKang concludes first cohort dosing in Phase I trial of NKT3964 for tumoursNiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for treating adults with advanced or metastatic solid tumours. The dose-escalation ...
γ-herpesvirus genomes encode an abundance of homologues of cellular factors, including cyclin and Bcl-2. These viral homologues differ from their cellular counterparts in that the viral proteins ...
"We are excited to outline a clear path for Zentalis to bring azenosertib to patients with Cyclin E1+ PROC,” said Ingmar Bruns, M.D., Chief Medical Officer. "In a patient population with a clear unmet ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback